Heart cells keep the rhythm by Van Epps, Heather L.
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The complement activation product 
C5a prevents heart cells from contract-
ing, according to Niederbichler and 
colleagues on page 53. This finding may 
help explain the cardiac dysfunction 
commonly seen in patients with septic 
shock—a disease caused by bacterial in-
fections that is characterized in part by 
the robust activation of the comple-
ment system.
A central component of septic shock 
is decreased heart function, which de-
prives tissues of oxygen and nutrients 
and can progress to fatal multiorgan 
failure. Past studies have shown that a 
“myocardial depressant factor” is re-
leased into the serum during sepsis, 
with most studies attributing the de-
pressant activity to proinflammatory 
cytokines released by immune cells re-
sponding to the infection.
Robust activation of the comple-
ment cascade is another hallmark of bac-
terial sepsis. Complement is a series of 
plasma proteins that helps destroy infect-
ing microbes and attracts immune cells 
to sites of infection. C5a activates im-
mune cells, such as neutrophils, which 
can then attack and kill the invading 
bacteria. But too much C5a can be dele-
terious, as blocking the protein or its re-
ceptor increases survival in rodent 
models of septic shock. This group pre-
viously showed that excessive C5a some-
how prevents the activation of MAP 
kinase signaling in neutrophils, which 
jams up downstream signals and robs the 
cells of their ability to destroy bacteria.
The receptor for C5a (C5aR) is also 
expressed on airway cells, including 
bronchial epithelial cells and smooth 
muscle cells, but a link between comple-
ment and sepsis-induced cardiac dys-
function had not been directly 
investigated. Niederbichler and col-
leagues now show that cardiomyocytes, 
which help control heartbeat, also ex-
press C5aR—possibly to increase blood 
flow in response to infection or stress.
But as with neutrophils, too much 
C5a was bad for cardiomyocytes. Treat-
ment of cardiomyocytes with high con-
centrations of C5a impaired their ability 
to contract. Blocking the interaction be-
tween C5a and its receptor in rats re-
lieved the sepsis-induced drop in blood 
pressure. The authors are now investi-
gating the molecular pathways that link 
C5aR signaling to the contractile ma-
chinery of the cell; they suspect that ex-
cessive C5a might induce a signaling 
paralysis in cardiomyocytes similar to 
that seen in neutrophils. 
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Cytokine therapy post–heart attack restores the expression of gap 
junction proteins and thus restores electrical connections between 
heart cells, according to a new study by Kuhlmann and colleagues 
(page 87). These heart cells, with better electrical connections, are 
able to pump with a more normal rhythm.
Restoring the function of damaged heart tissue is a new 
approach to the treatment of myocardial infarctions, or heart 
attacks. The scar tissue from heart attacks creates a roadblock for 
electrical conduction and can cause the heart to beat erratically. 
Indeed, erratic heartbeats—or arrhythmias—are the primary cause 
of death in patients who have had heart attacks.
Heart attack treatments range from blood-thinning and 
cholesterol-lowering drugs, which reduce the likelihood of 
developing blocked arteries, to implanted defibrillators that shock 
erratically beating hearts into line. But the idea of repairing damaged heart tissue is new. One promising repair 
approach involves the intravenous injection of two cytokines—G-CSF (granulocyte colony-stimulating factor) and 
SCF (stem cell factor)—which mobilize stem cells from the bone marrow (BM). Early studies suggested that these 
stem cells travel to the damaged heart and differentiate into functional heart cells called cardiomyocytes. Other 
studies, however, found no evidence that stem cells can become cardiomyocytes.
Kuhlmann and colleagues now confirm that G-CSF/SCF treatment in mice with heart damage causes BM-derived 
cells to enter the heart, but they show that virtually none of these cells become bona fide heart cells. The benefit of 
this treatment—which improved the heart’s pump function and protected against induced arrhythmias—instead 
correlated with enhanced expression of the gap junction protein connexin 43 on the surface of heart cells adjacent to 
the injured tissue. The expression of connexin 43, which provides the electrical connection between neighboring cells, 
is decreased after heart injury, thus reducing the conductive capacity between cells.
The connexin-inducing effect of G-CSF might be direct, as cardiomyocyte expression of the G-CSF receptor 
was increased in response to injury. But this possibility is difficult to test in vitro, as mouse cardiomyocytes grow 
poorly in culture. The authors are also investigating G-CSF–independent signaling pathways that induce the 
expression of connexin 43 in other cell types. 
G-CSF treatment restores the expression of connexin 43 on 
cardiomyocytes near areas of heart attack–induced damage (arrows).
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A new study by Ito and colleagues on page 7 may help 
explain why patients with a severe lung disease called chronic 
obstructive pulmonary disease (COPD) fail to respond to 
steroid treatment. Ito and colleagues show that steroids 
require the enzyme HDAC2 (histone deacetylase 2) to block the 
inflammatory transcription factor NF-κB. In patients with COPD, 
HDAC2 activity is reduced, rendering cells impervious to the 
soothing effects of steroids.
Steroids called glucocorticoids (GCs) are powerful 
antiinflammatory drugs used to treat chronic inflammatory 
disorders such as asthma and inflammatory bowel disease. But 
these drugs don’t work in patients with COPD—a chronic 
inflammatory disease of the lungs linked to cigarette smoking.
When working properly, GCs calm inflammation in two ways. 
They bind to the cytoplasmic glucocorticoid receptor (GR), which 
then binds to NF-κB and prevents it from activating 
inflammatory gene expression. At high concentrations, GCs also 
induce the expression of HDAC proteins.
Consistent with the induction of HDAC expression in 
antiinflammatory responses, this group had previously shown 
that patients with more severe COPD had decreased 
expression of HDAC2, probably due to oxidative damage to 
the enzyme inflicted by cigarette smoke. HDAC2 is most well-
known for plucking acetyl groups from histones, thus 
preventing the transcriptional machinery from binding to 
chromatin. But now Ito and colleagues find that HDAC2 also 
deacetylates GRs. GRs are acetylated in response to steroid 
binding, but must be deacetylated by HDAC2 to allow them to 
block NF-κB–driven inflammation.
Overexpressing HDAC2 in macrophages from patients with 
COPD restored GC-induced suppression of NF-κB–driven cytokine 
production. These data not only identify GR as the first 
nonhistone target for HDAC2, but also suggest that strategies 
aimed at increasing HDAC2 activity, combined with steroids, 
might be useful for treating patients with COPD. 
Glucocorticoid receptors must be deacetylated by HDAC2 to block 
NF-κB-driven gene expression.
Glucocorticoid receptors must be deacetylated by HDAC2 to block 
NF-κB-driven gene expression.
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Interferon (IFN)-α gives macrophages the upper 
hand against HIV, according to a study on page 
41. Peng and colleagues show that the cytokine 
IFN-α enhances the expression of the RNA-ed-
iting enzyme APOBEC3G, which mutates HIV 
DNA, thus triggering its degradation.
APOBEC3G is a close relative of the B 
cell–specific protein AID (activation-induced 
cytidine deaminase), which mutates immuno-
globulin DNA to generate high affinity anti-
bodies. APOBEC3G—which may have 
evolved as a regulator of endogenous retrovi-
ruses—recently emerged as an inhibitor of HIV 
replication in T cells, owing to its propensity to 
mutate retrotranscribed viral DNA. But HIV 
effectively counters this defense with the Vif 
protein, which binds to APOBEC3G and tar-
gets it for proteasomal degradation.
Boosting cellular levels of APOBEC3G 
might be an effective way to combat the de-
structive effects of Vif, but no APOBEC3G-
inducing factors had been identified. Now, 
Peng and colleagues show that IFNα—a 
known inhibitor of HIV replication—activates 
an IFN-responsive element in the APO-
BEC3G promoter in macrophages, thus driv-
ing APOBEC3G synthesis and overwhelming 
Vif’s capacity to degrade the protein.
But endogenous IFN-α, which is pro-
duced during viral infection, does not curtail 
HIV infection in vivo. This finding might be 
explained by the fact that T cells—the other 
major cell type targeted by HIV—do not ap-
pear to induce APOBEC3G expression in 
response to IFN-α. Besides investigating 
why the signal doesn’t get through to T cells 
(which express IFN receptors), the authors 
are now examining whether APOBEC3G 
expression or activity differs in myeloid cells 
that are resistant to HIV infection. Indeed, a 
recent study showed that the enzyme restricts 
HIV replication in resting T cells but be-
comes mired in an enzymatically inactive 
protein–RNA complex upon T cell activa-
tion, possibly explaining why HIV preferen-
tially replicates in activated T cells. 
The cellular protein APOBEC3G 
disrupts HIV replication 
when incorporated into new 
virions (shown budding 
from a macrophage).
The cellular protein APOBEC3G 
disrupts HIV replication 
when incorporated into new 
virions (shown budding 
from a macrophage).
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A genetic mutation that protects against HIV infection increases 
the risk of developing clinical West Nile virus (WNV) infection, 
according to Glass and colleagues on page 35.
The mutation in question is a 32-bp deletion in a gene that 
encodes the chemokine receptor CCR5, which was identified in 
1996 as a cellular coreceptor for HIV. Individuals homozygous for 
this mutation (CCR5∆32) are highly resistant to HIV infection, 
even when repeatedly exposed to the virus. This resistance was 
the theoretical basis for the development of therapeutic CCR5 
inhibitors, several of which are now in clinical trials. CCR5 
seemed like an ideal drug target, as people missing the receptor 
were healthy and no diseases or infections were known to be 
more frequent or severe in individuals homozygous for CCR5∆32. 
Mice appeared to be equally unfazed by the lack of CCR5.
But new evidence suggests that the lack of CCR5 is not 
completely innocuous. This group recently showed that infection 
with WNV—a mosquito-borne virus that has spread rapidly across 
the United States since 1999, often causing fatal encephalitis—
was uniformly fatal in mice lacking CCR5. This finding prompted 
the group to look for the CCR5∆32 allele in two cohorts of 
patients in the United States who had symptomatic WNV 
infections. They now report that 4–5% of the infected individuals 
were homozygous for the CCR5∆32 allele, compared with less 
than 1% of the general 
population, suggesting 
that the lack of CCR5 puts 
people at risk for 
developing clinical WNV 
infections. The magnitude 
of this risk is comparable 
to the magnitude of 
protection against HIV 
that is conferred by this 
genotype. It remains to be 
tested whether CCR5-
deficient humans, like 
mice, develop more severe 
disease because fewer 
protective immune cells gain access to the brain.
This study identifies not only the first genetic susceptibility 
factor for WNV infection but also the first association of the 
CCR5∆32 allele with susceptibility to an infectious disease. These 
data might also raise a red flag for the use of CCR5 inhibitors in 
HIV-infected patients—at least in areas endemic for WNV—as 
such inhibitors might increase the recipients’ vulnerability to 
severe WNV infection. 
Individuals homozygous for the 
CCR5∆32 allele are more likely to suffer 
from fatal West Nile Virus infection.
Individuals homozygous for the 
CCR5∆32 allele are more likely to suffer 
from fatal West Nile Virus infection.
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A study on page 239 shows that death-inducing T cells kill smooth muscle cells in atherosclerotic plaques. Sato 
et al. show that this lethal T cell activity is heightened in patients with heart disease, which could destabilize 
the plaques in these patients and make them more prone to rupture.
The narrowing of arteries is a natural process caused by the gradual deposition of fat and cholesterol into artery 
walls. The buildup of arterial plaques (atherosclerosis) is a long-term process that, for some, culminates in acute 
coronary syndromes (ACSs) such as heart attack and cardiac arrest. These acute attacks are caused by the sudden 
rupture of atherosclerotic plaques—an event that may happen more readily in some individuals than in others.
Plaques that contain immune cells such as macrophages and T cells are the most vulnerable to rupture, al-
though the mechanism behind this observation is not well understood. Now, Sato and colleagues show that 
CD4+ T cells that infiltrate atherosclerotic plaques trigger the death of vascular smooth muscle cells (VSMCs), 
a process proposed to destabilize the plaques.
The plaque-infiltrating T cells expressed high levels of TRAIL, a death receptor 
normally used by T cells and NK cells to destroy cancerous cells. The expression of 
this receptor was required for T cells to induce apoptosis in VSMCs (which expressed 
the TRAIL receptor DR5) both in vitro and in vivo. CD4+ T cells from patients with 
ACS expressed higher levels of TRAIL when activated and were more adept at trig-
gering VSMC apoptosis in vitro compared with T cells from healthy individuals, pos-
sibly explaining why these individuals developed acute disease while others were 
spared. What causes plaque-residing VSMCs to express DR5 and why T cells infil-
trate the plaques in some individuals is not yet known.
These results demonstrate that the TRAIL pathway—previously thought to in-
duce death only in cancer cells—can also trigger apoptosis in nontransformed cells. A 
recombinant form of TRAIL is currently in clinical trials for the treatment of certain 
cancers, a therapeutic approach that might need reevaluation in light of its potential 
negative effects on patients with atherosclerosis. 
TRAIL-expressing CD4+ T cells trigger 
apoptosis of vascular smooth muscle 
cells (red) in atherosclerotic plaques
TRAIL-expressing CD4+ T cells trigger 
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